Skip to main content
TipRanks
Go Ultimate75% OFF

Arbutus Biopharma (ABUS) Stock Statistics & Valuation Metrics

1,289 Followers

Total Valuation

Arbutus Biopharma has a market cap or net worth of $619.30M. The enterprise value is $620.04M.

Market Cap
$619.30M
Enterprise Value
$620.04M

Share Statistics

Arbutus Biopharma has 153,292,830 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
153,292,830
Owned by Insiders
19.68%
Owned by Institutions
56.19%

Financial Efficiency

Arbutus Biopharma’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -30.34%.

Return on Equity (ROE)
-0.44
Return on Assets (ROA)
-0.35
Return on Invested Capital (ROIC)
-30.34%
Return on Capital Employed (ROCE)
-0.31
Revenue Per Employee
741.21K
Profits Per Employee
-1.76M
Employee Count
19
Asset Turnover
0.15
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Arbutus Biopharma is 3.57. Arbutus Biopharma’s PEG ratio is 0.00.

PE Ratio
3.57
PS Ratio
3.41
PB Ratio
9.36
Price to FCF
2.80
Price to Operating Cash Flow
3.63
PEG Ratio
0.00

Income Statement

In the last 12 months, Arbutus Biopharma had revenue of 14.08M and earned -33.50M in profits. Earnings per share was -0.17.

Revenue
14.08M
Gross Profit
13.72M
Operating Income
-27.05M
Pretax Income
-33.50M
Net Income
-33.50M
EBITDA
-33.04M
Earnings Per Share (EPS)
-0.17

Cash Flow

In the last 12 months, operating cash flow was 221.00M and capital expenditures 0, giving a free cash flow of 221.00M billion.

Operating Cash Flow
221.00M
Free Cash Flow
221.00M
Free Cash Flow per Share
1.11

Dividends & Yields

Arbutus Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
35.70%
Earnings Yield
27.41%

Stock Price Statistics

Beta
0.74
52-Week Price Change
-10.79%
50-Day Moving Average
4.46
200-Day Moving Average
4.49
Relative Strength Index (RSI)
46.66
Average Volume (3m)
5.20M

Important Dates

Arbutus Biopharma upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 04, 2027
Ex-Dividend Date
―

Financial Position

Arbutus Biopharma as a current ratio of 15.73, with Debt / Equity ratio of 5.47%

Current Ratio
15.73
Quick Ratio
15.73
Debt to Market Cap
0.00
Net Debt to EBITDA
0.42
Interest Coverage Ratio
-278.88

Taxes

In the past 12 months, Arbutus Biopharma has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Arbutus Biopharma EV to EBITDA ratio is 1.61, with an EV/FCF ratio of 1.61.

EV to Sales
1.96
EV to EBITDA
1.61
EV to Free Cash Flow
1.61
EV to Operating Cash Flow
1.61

Balance Sheet

Arbutus Biopharma has $337.49M in cash and marketable securities with $328.00K in debt, giving a net cash position of $337.16M billion.

Cash & Marketable Securities
$337.49M
Total Debt
$328.00K
Net Cash
$337.16M
Net Cash Per Share
$2.20
Tangible Book Value Per Share
$0.43

Margins

Gross margin is 99.99%, with operating margin of 79.90%, and net profit margin of 121.17%.

Gross Margin
99.99%
Operating Margin
79.90%
Pretax Margin
121.17%
Net Profit Margin
121.17%
EBITDA Margin
121.23%
EBIT Margin
121.21%

Analyst Forecast

The average price target for Arbutus Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
1142.57%
EPS Growth Forecast
―

Scores

Smart Score
6
AI Score
68